Leonardo Drs, Inc. (DRS) — SEC Filings
Leonardo Drs, Inc. (DRS) — 23 SEC filings. Latest: 8-K (May 5, 2026). Includes 9 8-K, 6 10-Q, 2 DEF 14A.
View Leonardo Drs, Inc. on SEC EDGAR
Overview
Leonardo Drs, Inc. (DRS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 3 filed on Apr 1, 2026: This SEC Form 3 filing on April 1, 2026, is an initial statement of beneficial ownership of securities for Leonardo DRS, Inc. The filing details the ownership of securities by individuals associated with the company, including Jeffery Reuben III, whose mailing address is C/O AFFILIATED MANAGERS GROU
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 3 bullish, 20 neutral. The dominant filing sentiment for Leonardo Drs, Inc. is neutral.
Filing Type Overview
Leonardo Drs, Inc. (DRS) has filed 1 3, 1 4, 9 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 DEFA14A, 1 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of DRS's 20 recent filings, 0 were flagged as high-risk, 5 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $960M |
| Net Income | $72M |
| EPS | $0.26 |
| Cash Position | $309M |
| Operating Margin | 9.7% |
| Total Assets | $4,245M |
| Total Debt | $350M |
Key Executives
- Jeffery Reuben III
- Sarah E. Hatto
- David L. Van Hooser
- Michael J. Deitch
- Paul R. Murphy
Industry Context
Leonardo DRS operates within the defense and aerospace industry, characterized by long-term government contracts and significant R&D investment. The sector is heavily influenced by geopolitical stability, defense budgets, and technological advancements. Competition is intense, with major players vying for lucrative government contracts.
Top Tags
financials (5) · Defense Sector (3) · 10-Q (3) · Leonardo DRS (3) · Government Contracts (2) · Aerospace & Defense (2) · Military Technology (2) · Financial Performance (2) · corporate-governance (2) · proxy-statement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Q3 2025 Revenues | $960M | Up 18.2% from $812M in Q3 2024, indicating strong growth. |
| Q3 2025 Net Earnings | $72M | Increased 26.3% from $57M in Q3 2024, showing enhanced profitability. |
| Nine-Month 2025 Revenues | $2.588B | Up 14.9% from $2.253B in the prior nine-month period. |
| Nine-Month 2025 Net Earnings | $176M | Increased 41.9% from $124M in the prior nine-month period, a significant jump. |
| Revenue from DoD | 81% | Highlights high dependence on U.S. government contracts. |
| Cash and Cash Equivalents | $309M | Decreased from $598M at December 31, 2024, due to operating and financing activities. |
| Capital Expenditures | $90M | Increased from $56M in the prior nine-month period, indicating investment in operations. |
| Cash Dividends Paid | $72M | Paid during the nine months ended September 30, 2025, reflecting shareholder returns. |
| Diluted EPS (Q3 2025) | $0.26 | Up from $0.21 in Q3 2024, demonstrating per-share earnings growth. |
| Diluted EPS (Nine-Month 2025) | $0.65 | Up from $0.46 in the prior nine-month period, indicating strong per-share performance. |
| Q2 2025 Revenue | $725M | Increased 10.7% from $655 million in Q2 2024, indicating strong growth. |
| Q2 2025 Net Income | $62M | Increased 24% from $50 million in Q2 2024, demonstrating improved profitability. |
| Revenue Growth Rate | 10.7% | Year-over-year increase in revenue for Q2 2025, driven by defense contracts. |
| Net Income Growth Rate | 24% | Year-over-year increase in net income for Q2 2025, reflecting operational efficiency. |
| SEC File Number | 001-41565 | Identifies the company's filing history with the SEC. |
Forward-Looking Statements
- {"claim":"The market will likely view this as a clarification of ownership rather than a new divestment, as the '0' shares suggest a prior transaction or restructuring.","entity":"Leonardo DRS, Inc. stock","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Analysts may inquire further into the specific reasons for Leonardo US Holding, LLC's zero beneficial ownership, especially if it was a recent change from a significant stake.","entity":"Leonardo DRS, Inc. management","targetDate":"Next earnings call","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Leonardo Drs, Inc. (DRS)?
Leonardo Drs, Inc. has 23 recent SEC filings from Jan 2024 to May 2026, including 9 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DRS filings?
Across 23 filings, the sentiment breakdown is: 3 bullish, 20 neutral. The dominant sentiment is neutral.
Where can I find Leonardo Drs, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Leonardo Drs, Inc. (DRS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Leonardo Drs, Inc.?
Key financial highlights from Leonardo Drs, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DRS?
The investment thesis for DRS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Leonardo Drs, Inc.?
Key executives identified across Leonardo Drs, Inc.'s filings include Jeffery Reuben III, Sarah E. Hatto, David L. Van Hooser, Michael J. Deitch, Paul R. Murphy.
What are the main risk factors for Leonardo Drs, Inc. stock?
Of DRS's 20 assessed filings, 0 were flagged high-risk, 5 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Leonardo Drs, Inc.?
Recent forward-looking statements from Leonardo Drs, Inc. include guidance on {"claim":"The market will likely view this as a clarification of ownership rather than a new divestment, as the '0' shar and 1 other predictions.